A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Parkinson Disease
Interventions
DRUG

ropinirole monotherapy

ropinirole as monotherapy in Parkinson's disease

DRUG

placebo monotherapy

placebo as monotherapy in Parkinson's disease

Trial Locations (34)

10138

GSK Investigational Site, Tallinn

11375

GSK Investigational Site, Forest Hills

13419

GSK Investigational Site, Tallinn

23249

GSK Investigational Site, Richmond

30912

GSK Investigational Site, Augusta

33486

GSK Investigational Site, Boca Raton

33612

GSK Investigational Site, Tampa

45227

GSK Investigational Site, Cincinnati

51014

GSK Investigational Site, Tartu

90505

GSK Investigational Site, Torrance

91105

GSK Investigational Site, Pasadena

91355

GSK Investigational Site, Reseda

92708

GSK Investigational Site, Fountain Valley

93003

GSK Investigational Site, Ventura

194044

GSK Investigational Site, Saint Petersburg

214019

GSK Investigational Site, Smolensk

305007

GSK Investigational Site, Kursk

410012

GSK Investigational Site, Saratov

420012

GSK Investigational Site, Kazan'

450000

GSK Investigational Site, Ufa

454136

GSK Investigational Site, Chelyabinsk

463707

GSK Investigational Site, Sungnam -Gyeonggi-do

501757

GSK Investigational Site, Donggu Gwangju

614990

GSK Investigational Site, Perm

620102

GSK Investigational Site, Yekaterinburg

630091

GSK Investigational Site, Novosibirsk

644033

GSK Investigational Site, Omsk

660022

GSK Investigational Site, Krasnoyarsk

974 04

GSK Investigational Site, Banská Bystrica

813 69

GSK Investigational Site, Bratislava

831 03

GSK Investigational Site, Bratislava

602-715

GSK Investigational Site, Busan

138-736

GSK Investigational Site, Seoul

152-703

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01485172 - A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease | Biotech Hunter | Biotech Hunter